



SB 895: AN ACT CONCERNING CHANGES TO VARIOUS PHARMACY STATUTES

In 2020, the Connecticut Legislature passed a law to address the high cost of insulin for patients with diabetes. This legislation included a requirement for pharmacies and dispensers to report insulin to the state's Prescription Monitoring Program (PMP). Veterinarians are considered dispensers and fall under the same requirements that human doctors and pharmacies do for opioids, etc. The veterinary community has abided by the PMP law since its inception. As far as the new law is concerned, veterinarians aren't prescribing emergency insulin and the insulin they dispense to their animal patients typically isn't sold in human pharmacies. The CVMA doesn't believe it is necessary that veterinarians are included in this specific requirement to report insulin to the PMP.

We therefore respectfully request the Committee consider adding the following language to SB 895 to exempt veterinarians from this requirement.

Section 21(a)-254

(16) Each pharmacy, nonresident pharmacy, as defined in section 20- 627, outpatient pharmacy in a hospital or institution, and dispenser shall report to the commissioner, at least daily, by electronic means or, if a pharmacy or outpatient pharmacy does not maintain records electronically, in a format approved by the commissioner information for all insulin drugs, glucagon drugs, diabetes devices and diabetic ketoacidosis devices prescribed and dispensed by such pharmacy or outpatient pharmacy except that a veterinarian, licensed pursuant to chapter 384, that dispenses insulin drugs, glucagon drugs, diabetes devices and diabetic ketoacidosis devices for animal patients shall be exempt from these reporting requirements. Such pharmacy or outpatient pharmacy shall report such information to the commissioner in a manner that is consistent with the manner in which such pharmacy or outpatient pharmacy reports information for controlled substance prescriptions pursuant to subdivision (4) of this subsection. For the purposes of this subdivision, "insulin drug", "glucagon drug", "diabetes devices" and "diabetic ketoacidosis device" have the same meanings as provided in section 20-616.

Thank you for your consideration.